Danaher Corporation (DHR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
$236.98 +1.24% NYSE • Public Delayed / 60s Snapshot
Danaher Corporation (DHR) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-3.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D • SELL / AVOID
Cap $166.72B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+3.1% Base Target
WHALE OPTIONS TUG-OF-WAR:57% Call Buyers ($17.2M)
43% PutsMax Pain: $232.00
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)
How DHR Turns Every Dollar of Sales Into Real Bottom-Line Profit
Free Cash Flow:$5.26B (21.4% FCF Margin)
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $23.89B
FY24
Rev $23.88B
FY25
Rev $24.57B
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $24.57B | 59.1% | 19.1% | $3.61B | $5.26B | 6% |
| FY 2024 | $23.88B | 59.5% | 20.4% | $3.90B | $5.30B | 6.8% |
| FY 2023 | $23.89B | 44% | 21.8% | $4.76B | $6.09B | 7.4% |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring DHR)
- ✓Live walkthrough of DHR's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
DHR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.77%▲ ASCENDING CHANNEL
2026-10-30O $238.5H $238.5L $230.5C $232.2VOL 3.75M
RES: $256.1SUP: $173.6SMA50: $218.9SMA200: $201.1
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DHR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
34.2%/yr Implied 5Y Growth
vs. +2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DHR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
DHR → NVO Analyst Hypothesis
Novo Nordisk $6B+ annual API manufacturing expansions utilize downstream purification chromatography resins and single-use filtration consumables where Danaher Cytiva and Pall hold leading bioprocess share.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DHR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DHR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Danaher Corporation (DHR)?
In FY 2025 (10-K), DHR converted $24.6B of revenue into a 59.1% gross margin, 19.1% operating margin, and $5.3B in free cash flow (21.4% FCF margin).